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Several studies were undertaken to assess the psychometric properties (reliability and initial convergent and discriminant construct
validity) of the Neurological Quality of Life Questionnaire (NeuroQOL). The NeuroQOL contains 114 items answered in self report
Likert format, with higher scores reflecting better quality of life. Study one compared the questionnaire with existing quality of life mea-
sures (Symptom Distress Scale, Sickness Impact Profile) and a significant (p < 0.05) correlation was found. Studies two through five eval-
uated the relationship between the NeuroQOL and disease stage, psychological, neuropsychological and neurological measures and a
significant correlation was also found with each domain. The internal consistency reliability (Alpha = 0.96), split half reliability
(r12 = 0.97), and test-retest reliability (coefficients were 0.78 for 6 months and 0.67 for one year intervals between test and retest) were
all found to be high and adequately stable. Overall, these results indicate acceptable reliability and initial construct validity for the
NeuroQOL.
 2006 Published by Elsevier Ltd.












O1. IntroductionThe primary goals of health care are to increase life
expectancy and to improve well being (quality of life)
throughout a person’s life. Neurological illness poses con-
cerns, as limited means of expression, fatigue, and cognitive
decline make quality of life (QOL) assessment and judg-
ment of its efficacy difficult.1 Quality of life is an issue for
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E-mail address: tparsons@neurology.unc.edu (T.D. Parsons).tia,5,6 Alzheimer’s disease7,8 and epilepsy.9 As in other dis-
eases, it is often the case that people with HIV do not wish
to have life-prolonging measures taken unless this results in
an adequate quality of life. The pathology, social stigma,
and self-blame of people living with HIV/AIDS make pa-
tients more susceptible to depression symptoms as well as
lower perceived QOL. The importance of QOL has been
noted by many researchers and may be the most important
outcome in progressive diseases such as HIV infection,
where there is no current cure.10
Quality of life can be broadly defined as the subjective
perception of life satisfaction and well-being, which includes
the areas of bodily function and health status, psychological
well-being, cognition, social interactions, self-care activities,
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important implications for health care in general and HIV
infection in particular. However, there are important differ-
ences in the ways in which people view QOL. There are dis-
agreements related to the subjective nature of people’s
descriptions of their QOL. Further, there are differences
among health care professionals related to subjective QOL
valuations of illness and injury, and health care.11 Hence,
it is of importance that health professionals find a reliable
measure that does not ignore the patient’s perspective on
QOL.
Patients afflicted with HIV often exhibit neurologic,12,13
neurocognitive,14–18 as well as affective disorders such as
depression and anxiety.19 In fact, lower QOL scores have
been found to be associated with a diagnosis of HIV and
with disease-related symptoms.20–23
Quality of life related measures that are disease-specific
require a greater level of emphasis upon the unique con-
cerns of those affected by the relative disease. Although
there are a number of QOL measures for high-prevalence
conditions, there are fewer measures addressing the QOL
of people with neurologic injury or disease. Since many
QOL measures have not demonstrated sufficient validity,
many examiners construct their own instruments. While
this may proffer qualitative information, problems arise
when attempts are made to validate these measures quanti-
tatively. Given the fact that cognitively impaired HIV pa-
tients are less likely to employ effective strategies to
manage stressors and in turn to alleviate symptoms of
depression and anxiety,24 it is important that there be a
reliable QOL measure that provides a broad conceptual
model taking into account domains beyond specific
health-related aspects of HIV-related illness.
The Neurological Quality of Life Questionnaire (Neuro-
QOL) was developed to provide a measure of quality of life
in HIV infection. The NeuroQOL was developed on a
broad conceptual model taking into account domains be-
yond specific health-related aspects, and can utilize both
unidimensional (overall summary score) and multidimen-
sional (domain profiles) constructs. The present study re-
ports the initial psychometric estimates (reliability and
validity) of this instrument. Further, our goal was to assess
whether the instrument significantly correlated with hypo-
thetically similar constructs (convergent construct validity)
and discriminant construct validity.
2. Method
The University of North Carolina Institutional Review
Board approved the study, and all subjects gave informed
consent for participation. Subjects were recruited and inter-
viewed from June, 1991 to January, 1993. Subjects were
administered the NeuroQOL by a clinical psychologist or
trained nurse clinician as part of larger instrument proto-
cols. All were either admitted as inpatients to the NIH
General Clinical Research Center at the University of
North Carolina (UNC) at Chapel Hill or interviewed at








Two separate subject samples participated in the five
validity studies. The first sample participated in Study
one. The first sample consisted of 63 subjects who were vol-
untary participants recruited from an infectious diseases
clinic. Twenty-one subjects were asymptomatic (ASX,
CDC II–III), 21 met criteria for AIDS-related complex
(ARC, CDC IVA) and 21 met criteria for acquired immune
deficiency syndrome (AIDS, CDC IVB-E). Subjects had a
mean age of 33.92 years (range, 19–49, SD = 6.80) with a
mean of 13.30 years of education (range, 2–23,
SD = 3.14). Forty-three (68%) subjects were white, 18
(28%) were black, two (4%) were of other ethnic back-
grounds. Fifty-four were male and nine were female.
The second sample participated in Studies two through
five. The second sample consisted of 85 subjects who were
voluntary participants in the AIDS Neurological Center
longitudinal study. Fifteen subjects were high-risk HIV
seronegative controls (CTRL), 32 subjects were asymp-
tomatic (ASX, CDC II–III), 25 met criteria for AIDS-
related complex (ARC, CDC IVA) and 13 met criteria
for acquired immune deficiency syndrome (AIDS, CDC
IVB-E). Subjects had a mean age of 35.97 years (range,
21–65, SD = 9.08) with a mean of 14.28 years of educa-
tion (range, 5–22, SD = 2.91). Risk factors included
homosexual contact in 73 (86%), exposure to blood prod-
ucts in four (5%), heterosexual contact in three (4%), and
intravenous drug abuse in five (6%). Sixty-nine (81%) sub-
jects were white, 13 (15%) were black, three (4%) were of
other ethnic backgrounds. Eighty-one were male and four
were female.
2.2. Procedure
At each evaluation, a neurologist conducted a quantified
previously validated examination particularly sensitive to
the changes found in HIV disease. A neuropsychologist
administered the NeuroQOL, and conducted detailed psy-
chological and neuropsychological evaluations that have
also been validated as sensitive to the neurocognitive
changes found in HIV disease.
2.3. Instruments
The Neurological Quality of Life Questionnaire (Neu-
roQOL) is a self report instrument which assesses 11 do-
mains: security, food, housing, financial, productivity,
social support, relationships, psychological health, physi-
cal health, substance abuse, and cognitive/neurological
problems. The NeuroQOL questionnaire contains 114
items answered in Likert format. The items are summed
for a total score, with higher scores reflecting better
quality of life.
The Sickness Impact Profile (SIP) is a self-report instru-
ment with 136 items in 12 domains and summed into two
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The Symptom Distress Scale (SDS) is a self-report
instrument with 13 items answered in a Likert format.26
The Brief Symptom Inventory (BSI)27 is a self-report
instrument measuring nine factors: somatization, obses-
siveness, interpersonal sensitivity, depression, anxiety, hos-
tility, phobic anxiety, paranoid ideation and psychoticism.
Three global measures of psychological functioning are de-
rived from the BSI: Positive Symptom Total, Positive
Symptom Distress Index and the Global Severity Index.
The Profile of Mood States (POMS)28 is a self-report
instrument measuring six factors: tension, anger, depres-
sion, vigor, fatigue and confusion.
A complete standardized neurological history and clini-
cal examination expanded from the AIDS Clinical Trials
Group (ACTG) Full Neurologic Exam was utilized.
The neuropsychological battery assessed the areas of
gross motor control, fine motor control, verbal recent
memory, figural recent memory, concentration/speed of
mental processing, initation/inhibition/mental flexibility,
tactile perception, visuospatial/construction, and language.
Individual test scores were externally standardized using z-
scores based on normative data. The z-scores were derived
from age and education-based norms available in the liter-
ature. Z-scores were summed within factors, and overall
for a total score.
3. Results
3.1. Psychometric properties (reliability)
Full scale scores ranged from 184 to 435, with a mean of
339.18 (SD = 55.03) for the sample. Reliability coefficients,
which set the upper limit on test validity, were computed.
The internal consistency reliability estimate for the full
scale was high (Alpha = 0.96). Table 1 presents the reliabil-
ity coefficients, item total correlations and coefficients with
the item removed for both raw and standardized variables.
See Table 2 for reliability coefficients for the Quality of Life
Domains.
Split half reliability was assessed using an ‘odd-even’
paradigm. All odd-numbered items were compared to all
even-numbered items. Split half reliability was found to
be high (r12 = 0.97).
Test-retest reliability for the full scale was estimated.
Subjects were tested and a subset were then retested at 6
months (n = 59) and 1 year (n = 39). Test-retest reliability
results indicated that the instrument has more than ade-
quate stability over time. At 6 months between test and ret-
est the coefficient was 0.78. At the 1 year interval between
test and retest the coefficient was 0.67.
3.2. Psychometric properties (validity)
Study one (QOL measures): For the first sample
(n = 63), NeuroQOL total scores ranged from 130 to 424,
with a mean of 296.37 (SD = 62.95). The NeuroQOL total







lated with the Sickness Impact Profile total score. The Neu-
roQOL total score was significantly (r [61] = 0.79,
p < 0.0001) correlated with the Symptom Distress Scale.
The NeuroQOL total score was also significantly (rs
[61] = 0.44, p < 0.0005) correlated with the number of
AIDS-related hospital admissions.
Study two (disease stage): For the second sample
(n = 85), NeuroQOL total scores ranged from 184 to 435,
with a mean of 339.18 (SD = 55.03). NeuroQOL total
scores were significantly (F3,84 = 14.21, p < 0.0001) differ-
ent across disease stage (CTRL = ASX > ARC > AIDS).
The NeuroQOL domains significantly (p < 0.001) differing
across disease stage were physical health, cognitive/neuro-
logical problems, psychological health, relationships, finan-
cial and productivity. NeuroQOL total scores were
significantly (r [83] = 0.25, p < .05) correlated with absolute
CD4+ cell counts. Table 3 contains results from compari-
sons of quality of life domains across HIV disease stages.
Study three (psychological): NeuroQOL total scores sig-
nificantly (r [83] = 0.49 to .060, p < 0.0001) correlated
with the POMS factors of tension, depression, anger, vigor,
fatigue, confusion. NeuroQOL total scores significantly
(r [83] = 0.32 to 0.69, p < 0.005) correlated with the
BSI factors of somatization, obsessive, interpersonal
sensitivity, depression, anxiety, hostility, phobia, paranoid
ideation, and psychoticism.
Study four (neuropsychological): NeuroQOL total
scores significantly (r [83] = 0.48, p < 0.0001) correlated
with the neuropsychological total z-score. The neuropsy-
chological domains of gross motor control, fine motor con-
trol, verbal recent memory, concentration/speed of mental
processing, initation/inhibition/mental flexibility were also
significantly correlated with the NeuroQOL total score (r
[83] = 0.33–0.46, p < 0.005).
Study five (neurological): NeuroQOL total scores signif-
icantly (p < .05) correlated with the ACTG full neurologi-
cal exam summary scores. neuroqol was significantly
correlated with overall dementia (rs [83] = 0.26, p <
.05), Overall CNS motor dysfunction (rs [83] = .31,
p < .01), overall peripheral neuropathy (rs [83] = 0.38, p
< .001), and AIDS dementia staging (rs [83] = 0.41, p <
0.0001). Table 4 contains results from comparisons of qual-
ity of life with both the presence and the absence of neuro-
logical dysfunction.
4. Discussion
This paper assessed the psychometric properties of the
Neurological Quality of Life Questionnaire (NeuroQOL),
a general measure of quality of life in HIV infection. From
the results of initial reliability analysis, it appears that the
NeuroQOL is psychometrically sound and warrants con-
sideration as an effective and reliable measure of the life
satisfaction and subjective well-being of those with HIV
infection.
According to Nunnally,29 the upper limit for the reliabil-


















Raw and standardized reliability coefficients for the full scale and by item
Domain Question Raw variables Standard variables
Correlation with total Alpha Correlation with total Alpha
Security
1. I feel safe where I live 0.21 0.96 0.21 0.96
2. Crimes happen in my neighborhood 0.13 0.96 0.15 0.96
3. I feel safe going out at night where I live 0.11 0.96 0.12 0.96
4. I have to lock the doors where I live 0.06 0.96 0.05 0.96
5. I know my needs will be met 0.44 0.96 0.44 0.96
Food
6. I have enough food to eat 0.34 0.96 0.33 0.96
7. I usually have balanced meals 0.37 0.96 0.36 0.96
8. I eat the right foods most of the time 0.33 0.96 0.32 0.96
9. I can afford the food I need 0.40 0.96 0.39 0.96
Housing
10. I have my own place to stay 0.24 0.96 0.22 0.96
11. It is crowded where I live 0.11 0.96 0.12 0.96
12. It is always clean where I live 0.32 0.96 0.34 0.96
13. The place where I live needs fixing up 0.28 0.96 0.30 0.96
14. It is always warm enough in my home 0.35 0.96 0.35 0.96
15. Sometimes it is too hot or cold in my house 0.31 0.96 0.31 0.96
16. I live in a good place 0.33 0.96 0.33 0.96
17. I have nowhere to live 0.02 0.96 0.04 0.96
Financial
18. I make enough money 0.45 0.96 0.41 0.96
19. I have a good job 0.51 0.96 0.46 0.96
20. I have enough to make ends meet 0.42 0.96 0.38 0.96
21. I have to depend on other’s support now 0.33 0.96 0.31 0.96
22. I have enough to live on 0.43 0.96 0.41 0.96
23. I have had a lot of training for my job 0.34 0.96 0.30 0.96
24. I have adequate job security 0.48 0.96 0.45 0.96
25. I have trouble paying my bills 0.30 0.96 0.30 0.96
Productivity
26. I can do as much as I used to 0.61 0.95 0.58 0.96
27. I can get around as much as I used to 0.57 0.96 0.54 0.96
28. I get tired easily now 0.42 0.96 0.42 0.96
29. I am able to do all the things I want to 0.49 0.96 0.46 0.96
30. I feel like I get things done 0.61 0.96 0.60 0.96
31. I have to stay in bed a lot 0.67 0.95 0.67 0.96
32. I have problems working 0.46 0.96 0.46 0.96
33. I am as capable as I used to be 0.54 0.96 0.50 0.96
Social Support
34. I feel supported by others 0.32 0.96 0.30 0.96
35. I have lots of friends 0.34 0.96 0.32 0.96
36. I have people I can rely on 0.37 0.96 0.36 0.96
37. Other people help me when I need it 0.39 0.96 0.38 0.96
38. I feel I can depend on others 0.39 0.96 0.37 0.96
39. I have family or friends who help me out 0.35 0.96 0.34 0.96
40. I have been discriminated against 0.13 0.96 0.14 0.96
Relationships
41. I have others close to me 0.46 0.96 0.44 0.96
42. I am close to my family 0.21 0.96 0.19 0.96
43. I have a significant other 0.42 0.96 0.38 0.96
44. I have many close friends 0.34 0.96 0.32 0.96
45. I am in love with someone 0.32 0.96 0.28 0.96
46. I have been interested in sex 0.32 0.96 0.27 0.96
47. Sex has been important to me 0.24 0.96 0.20 0.96
48. I could have gotten along without sex 0.25 0.96 0.23 0.96
49. I feel lonely 0.52 0.96 0.53 0.96
50. I have sex regularly 0.47 0.96 0.43 0.96
51. My family and friends want to see me 0.30 0.96 0.28 0.96
(continued on next page)
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Domain Question Raw variables Standard variables
Correlation with total Alpha Correlation with total Alpha
Psychological
52. I have had trouble sleeping 0.50 0.96 0.49 0.96
53. I have been sleeping too much 0.49 0.96 0.51 0.96
54. I have lost weight 0.43 0.96 0.42 0.96
55. I have gained weight 0.22 0.96 0.22 0.96
56. My appetite is fine 0.34 0.96 0.33 0.96
57. I eat less now 0.29 0.96 0.29 0.96
58. I have felt slowed down 0.56 0.96 0.55 0.96
59. I have felt restless 0.48 0.96 0.51 0.96
60. I have felt tired or unable to get things done 0.58 0.96 0.59 0.96
61. I have felt worthless 0.53 0.96 0.56 0.96
62. I have had trouble concentrating 0.58 0.96 0.61 0.96
63. I have had trouble making decisions 0.57 0.96 0.59 0.96
64. I have been crying more 0.31 0.96 0.35 0.96
65. I have had thoughts about death 0.45 0.96 0.47 0.96
66. I have thoughts of ending my life 0.37 0.96 0.40 0.96
67. I have felt hopeless 0.49 0.96 0.52 0.96
68. I have been nervous or worried 0.46 0.96 0.50 0.96
69. I have been a little afraid 0.44 0.96 0.47 0.96
70. I have been tense 0.31 0.96 0.35 0.96
71. I have felt shaky 0.44 0.96 0.48 0.96
72. I have had panic spells 0.29 0.96 0.32 0.96
73. I have felt uneasy in crowds 0.44 0.96 0.47 0.96
74. I have been suddenly scared for no reason 0.35 0.96 0.39 0.96
75. I have been under some stress 0.20 0.96 0.23 0.96
76. I have felt fatigued 0.57 0.96 0.57 0.96
77. My stomach has been upset 0.41 0.96 0.43 0.96
Physical
78. I have been ill 0.58 0.96 0.59 0.96
79. I have been feeling well 0.47 0.96 0.46 0.96
80. I have had some infections 0.33 0.96 0.33 0.96
81. I have had some pains 0.48 0.96 0.50 0.96
82. I have had fevers 0.54 0.96 0.55 0.96
83. I have had chills or night sweats 0.51 0.96 0.53 0.96
84. I have been coughing 0.44 0.96 0.45 0.96
85. I have had mouth infections 0.41 0.96 0.43 0.96
86. I have had some trouble breathing 0.49 0.96 0.51 0.96
87. I have had some blurry vision or eye problems 0.41 0.96 0.42 0.96
89. I have had some diarrhea 0.48 0.96 0.51 0.96
88. I have had some nausea or vomiting 0.50 0.96 0.53 0.96
90. I have had skin rashes 0.39 0.96 0.40 0.96
91. I have had some soreness 0.56 0.96 0.57 0.96
92. I have to take a lot of medications 0.40 0.96 0.39 0.96
93. I have to give up work due to my health 0.42 0.96 0.39 0.96
94. I have trouble walking 0.44 0.96 0.43 0.96
Substance abuse
95. I have been drinking more than I should 0.11 0.96 0.13 0.96
96. I have gotten into trouble while drinking or doing drugs 0.27 0.96 0.31 0.96
97. I have used some drugs 0.35 0.96 0.37 0.96
98. I have had problems with alcohol or drugs 0.08 0.96 0.10 0.96
99. Others feel I have had problems with alcohol/drugs 0.18 0.96 0.21 0.96
100. I have felt I needed to keep drinking or doing drugs 0.23 0.96 0.26 0.96
101. I have been smoking 0.29 0.96 0.28 0.96
Cognitive
102. I have trouble paying attention to things 0.56 0.96 0.59 0.96
103. I lose my train of thought 0.59 0.96 0.61 0.96
104. I have trouble concentrating 0.59 0.96 0.61 0.96
105. I have been confused 0.53 0.96 0.56 0.96
106. I have had some memory lapses 0.55 0.96 0.56 0.96
107. I am more forgetful 0.55 0.96 0.57 0.96
108. I am slower than I used to be 0.65 0.95 0.65 0.96
109. I am as organized as I used to be 0.38 0.96 0.38 0.96
(continued on next page)
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Domain Question Raw variables Standard variables
Correlation with total Alpha Correlation with total Alpha
110. I have had some trouble with coordination 0.56 0.96 0.57 0.96
111. I have had some pain in my arms or legs 0.51 0.96 0.50 0.96
112. I have numbness or tingling in my arms or legs 0.56 0.96 0.55 0.96
113. I have had a change in my math abilities 0.41 0.96 0.42 0.96
114. I am having some difficulties with household tasks 0.62 0.96 0.63 0.96
Note: Cronbach Coefficient Alpha for all raw variables = 0.96; Cronbach Coefficient Alpha for all standardized variables = 0.96.
Table 2







Social support 0.867 0.874
Relationships 0.820 0.817
Physical health 0.922 0.928
Psychological health 0.902 0.906
Substance abuse 0.650 0.735
Cognitive/neurological 0.912 0.921
Table 3
Quality of life domains across HIV disease stage
NeuroQOL domains CTRL ASX ARC AIDS
Total* 384.33 356.56 323.84 286.69
Security 13.20 14.06 13.80 12.62
Food 13.46 12.00 11.88 10.69
Housing 26.93 26.47 25.88 25.14
Financial* 24.40 19.00 15.64 14.77
Productivity* 27.47 23.09 17.84 14.23
Social Support 20.87 21.28 19.84 19.08
Relationships* 31.87 29.72 27.68 20.85
Psychological health* 89.93 83.63 79.68 72.08
Physical health* 62.87 59.38 49.24 41.39
Substance abuse 26.13 24.81 23.56 25.23
Cognitive/neurological* 47.20 43.13 38.80 30.62
Note: CTRL = Control; ASX = Asymptomatic; ARC = AIDS related
complex.
* (Significance at least p < 0.001).
Table 4
Quality of life scores by presence/absence of neurological dysfunction
Dysfunction NeuroQOL total scores
Absent Present
Dementia 343.05 (52.19) 275.80 (67.96)
CNS motor 344.15 (52.41) 290.13 (59.71)
Neuropathy 353.00 (51.59) 310.07 (51.29)
ADC 351.25 (49.33) 298.75 (54.92)
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Ftant decision-making or classification is based on the
results, like IQ tests or measures that determine the course
of and outcome of treatment. An instrument used in this
manner should have full-scale reliability coefficients of
internal consistency that are above 0.90. The internal con-
sistency reliability coefficient for the NeuroQOL question-
naire was 0.96 and therefore above both of these
standards. This suggests that the NeuroQOL questionnaire
has relatively minimal levels of random error and a rela-
tively homogenous sampling of items that appear to be
measuring a similar attribute of quality of life.
Beyond a high level of internal consistency, the Neuro-
QOL also appears to have strong test-retest reliability. In
order for a measure to represent the enduring status of a
particular construct, like quality of life, it must remain rel-
atively stable over time. In the absence of this stability, the
validity of one’s conclusions about this measure is more
susceptible to measurement error and factors that are
external to the test itself. For the NeuroQOL, the test-retest
reliability coefficients were 0.78 and 0.67 after 6 and 12
months, respectively. This reflects high temporal stability,
and the strength of these coefficients after such protracted
periods of 6 and 12 months, compared to 2 weeks or 1
month, reduces the possibility that these findings are due
to practice effects. Moreover, the relative disparity between
these test-retest coefficients and the internal consistency
coefficient suggests that this measure maintains temporal
stability while retaining sensitivity to situational factors
that may influence quality of life. Individuals who have
HIV infection are highly susceptible to fluctuations in those
factors that influence quality of life, like the ebb and flow
of physical and cognitive symptoms, as well as vacillations
in finances, relationships, and psychological factors. There-
fore, the NeuroQOL appears to have high temporal stabil-
ity while retaining an appropriate level of sensitivity to
situational or circumstantial factors that may occur in the
lives of those with HIV infection.
The studies presented in this paper also demonstrated
adequate construct validity for the NeuroQOL question-
naire. Assessment of convergent construct validity revealed
that the NeuroQOL correlated with two other quality of life
instruments, the SIP and SDS, and with the number of
AIDS-related hospital admissions. As discussed previously,
health-related QOL measures a patient’s perceived physical
and mental well-being over time in order to gain insight into
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life pertains to a patient’s ‘‘perceived’’ well-being, consis-
tently and reliably measuring quality of life is difficult, espe-
cially for neurologically impaired populations. The nature
of neurological illness poses serious questions of reliably
assessing quality of life. Whereas physically debilitating dis-
orders may pose difficulties in actually filling out a self-re-
port assessment, neurological deficits put in to question a
patient’s ability to answer questions correctly. Despite these
concerns, the NeuroQOL was found to directly correlate
with Sickness Impact Profile total scores, the Symptom
Distress Scale, and with the number of AIDS-related hospi-
tal admissions. In addition, according to Study five, the
NeuroQOL was significantly correlated with overall demen-
tia, Overall CNS motor dysfunction, overall peripheral neu-
ropathy, and AIDS dementia staging. These results indicate
that the NeuroQOL is an effective tool in assessing quality
of life in cognitively impaired neurological populations, at
least prior to profound dementia.
Significant decreases in quality of life scores were found
to be associated with advancing HIV disease stage and
decreasing CD4+ cell counts. While health-centered mea-
sures focus mainly on verifiable physical health and daily
function, person-centered measures reveal how the individ-
uals themselves actually view their quality of life regardless
of observable deficits. As patients adapt to disabilities
(whether cognitive or physical in nature) perceived quality
of life improves. Because of changes in coping skills and
adaptation to disability, not all factors associated with
quality of life change at the same rate. Specifically, in Study
two, reported quality of life decreased with disease progres-
sion relative to overall total score and in relation to finan-
cial stability, productivity, relationships, psychological and
physical health, and cognitive/neurological status.
Quality of life (NeuroQOL total scores) was found to
decrease with increasing psychological distress. According
to Study three, psychological factors directly affect the per-
ceived quality of life of patients. QOL scores were found to
correlate with symptoms of tension, depression, anger, vig-
or, fatigue, confusion, anxiety and hostility. This is a par-
ticularly important factor when assessing QOL in
patients with HIV infection, as the pathology and social
stigma associated with the disease leads to greater levels
of depression and anxiety. Considering Murrell’s sugges-
tion,1 discussed earlier, that a patient’s values and percep-
tions of their normal abilities adapt as they become
accustomed to disabilities, depressive symptoms may have
a stronger impact than actual cognitive impairment on self-
reported QOL. This would suggest that special attention
should be placed on addressing psychological distress, anx-
iety and depression in the treatment of HIV infection.
Quality of life, as measured by the NeuroQOL, was
found to decrease with increasing neuropsychological
impairment. In Study four, the neuropsychological do-
mains of gross motor control, fine motor control, verbal re-
cent memory, concentration, processing speed, and








Evidence of discriminant construct validity was also
found in that NeuroQOL total scores were found to de-
crease as neurological dysfunction increased. NeuroQOL
domains not expected to be related to measures of dysfunc-
tion (e.g. the NeuroQOL domains of security, housing,
food, substance abuse) were not correlated with neurolog-
ical dysfunction.
Although developed primarily for the assessment of sub-
jective self-reports of neurocognitive and motor impair-
ments that occur with HIV, the NeuroQOL appears to
proffer an enhancement to current protocols (SIP, Notting-
ham Health Profile and SF-36) and disease-specific mea-
sures for other degenerative neurological disorders.
Future studies may investigate the generalizability of the
NeuroQOL for use with Parkinson’s disease, vascular
dementia, Alzheimer’s disease, and epilepsy. Incorporation
of the NeuroQOL into clinical trials in neurology may en-
hance QOL assessment. While current clinical trials may
make use of QOL measures, these are usually as secondary
outcome measures that do not adequately represent the full
scope of the impact of disease on an individual with a
chronic neurological disorder.
Overall, the NeuroQOL questionnaire appears to have
high homogeneity and temporal stability. Quality of life
has become increasingly important among those suffering
from progressive diseases, like HIV infection. As many
are living longer lives in the developed world with ad-
vanced antiretroviral treatment, concerns about maximiz-
ing life experience and well-being become paramount.
However, in order to assess quality of life in these individ-
uals, the field of health care and its practitioners need a reli-
able measure that can be used to determine the efficacy of
interventions, inform treatment, and shape overall life sat-
isfaction. From the foregoing results, the NeuroQOL ap-
pears to represent such a measure.Acknowledgements
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